[Skip to Navigation]
July 1986

Antihypertensive Therapy With Triamterene-Hydrochlorothiazide vs Amiloride-Hydrochlorothiazide: Comparison of Effects on Urinary Prostaglandin E2 Excretion

Author Affiliations

From the University of South Dakota School of Medicine and the Royal C. Johnson Veterans Administration Medical Center, Sioux Falls.

Arch Intern Med. 1986;146(7):1312-1314. doi:10.1001/archinte.1986.00360190076010

• Amiloride hydrochloride has now been recognized as a safe and effective potassium-sparing diuretic alternative to triamterene with a similar mechanism of pharmacologic activity. Studies were undertaken to assess the difference between therapy with the triamterene-hydrochlorothiazide combination (Dyazide) and an amiloride hydrochloride-hydrochlorothiazide combination (Moduretic) on renal prostaglandin production, since an increase in renal prostaglandin synthesis has been shown to mediate or enhance the pharmacologic action of certain diuretic drugs. Eight subjects treated for four weeks with triamterene-hydrochlorothiazide were compared with nine patients similarly treated with amiloride-hydrochlorothiazide. A 24-hour urine sample for prostaglandin E2 (PG E2) assay was collected under control conditions and after six weeks of therapy with either diuretic in all patients. The PGE2 excretion increased in the amiloride-hydrochlorothiazide-treated group; in the other group PGE2 excretion actually declined. It is concluded from these studies that therapy with amiloride-hydrochlorothiazide enhanced renal PGE2 production, whereas that with triamterene-hydrochlorothiazide actually decreased renal PGE2 production. This difference Is an important renal consequence of the use of either drug and should be considered In the choice between these diuretic combinations.

(Arch Intern Med 1986;146:1312-1314)

Add or change institution